| TOTAL: $25M | ||||
| Year to Date: $938.65M | ||||
| Company (Symbol)#* | Partner (Country) | Amt. (M) | Triggering Event | Details (Date) |
| Coley Pharmaceuticals Group Inc. (COLY) | GlaxoSmithKline plc (UK) | $3 | Milestone payment | For the start of GSK's Phase III trial in non-small-cell lung cancer of an immunotherapeutic cancer vaccine containing Coley's VaxImmune vaccine adjuvant (10/26) |
| Curis Inc. (CRIS) | Genentech Inc. (NYSE:DNA) | $3 | Milestone payment | For the initiation of an expansion cohort in its ongoing Phase I trial of a systemically administered Hedgehog antagonist (10/16) |
| Genmab A/S (Denmark; CSE:GEN) | F. Hoffmann-La Roche Ltd. (Switzerland) | ND | Milestone payment | For Roche's filing of a clinical trial application with British regulatory authorities for a Genmab antibody (10/2) |
| ImmunoGen Inc. (IMGN) | Sanofi-Aventis (France) | $1 | Milestone payment | For the advancement of the TAP compound SAR3419 into Phase I testing (10/17) |
| Incyte Corp. (INCY) | Pfizer Inc. | $10 | Milestone payment | For the filing and acceptance of an investigational new drug application for INCB8696, a CCR2 antagonist for multiple sclerosis (10/11) |
| Isis Pharmaceuticals Inc. (ISIS) | iCo Therapeutics Inc.* (Canada) | $1.25 | Milestone payment | For the initiation of Phase I trials of iCo-007 for the treatment of various eye diseases (10/9) |
| Isis Pharmaceuticals Inc. (ISIS) | Ortho-McNeil Inc. (unit of Johnson & Johnson) | $5 | Milestone payment | For the start of a clinical trial of ISIS 325568, which has demonstrated improved glucose control in animal models of Type II diabetes (10/2) |
| Ligand Pharmaceuticals Inc. (LGND) | Wyeth | $0.25 | Milestone payment | For the submission by Wyeth of a marketing authorization application in Europe for use of bazedoxifene in the prevention and treatment of osteoporosis (10/15) |
| NPS Pharmaceuticals Inc. (NPSP) | Kirin Pharma (Japan) | ND | Milestone payment | For the approval in Japan of cinacalcet hydrochloride to treat secondary hyper-parathyroidism (10/25) |
| Seattle Genetics Inc. (SGEN) | MedImmune Inc. (unit of AstraZeneca plc; UK; LSE:MDI) | $1.5 | Milestone payment | For the exercise of an option to obtain an exclusive license to a second antigen target under their existing antibody-drug conjugate collaboration (10/31) |
| Targeted Genetics Corp. (TGEN) | Amsterdam Molecular Therapeutics BV (the Netherlands) | ND | Milestone payment | As part of a licensing agreement that provides AMT with non-exclusive rights to patents covering Adeno-Associated Virus type 1 (10/4) |
| Zealand Pharma AS* (Denmark) | Wyeth Pharmaceuticals | ND | Milestone payment | For the advancement of the first orally available gap junction modifier ZP1609 into Phase I trials in the U.S. (10/10) |
|
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. * Private company. Currency conversions are based on exchange rates at the time of the deal. ND = Not disclosed. OTC BB = Over-the-Counter Bulletin Board. | ||||
